Role of Quality of Life as Endpoint for Inflammatory Bowel Disease Treatment

Cristina Calviño-Suárez, Rocío Ferreiro-Iglesias, Iria Bastón-Rey and Manuel Barreiro- de Acosta
Additional contact information
Cristina Calviño-Suárez: IBD Unit, Gastroenterology Department, University Hospital of Santiago de Compostela, 15706 Santiago de Compostela, Spain
Rocío Ferreiro-Iglesias: IBD Unit, Gastroenterology Department, University Hospital of Santiago de Compostela, 15706 Santiago de Compostela, Spain
Iria Bastón-Rey: IBD Unit, Gastroenterology Department, University Hospital of Santiago de Compostela, 15706 Santiago de Compostela, Spain
Manuel Barreiro- de Acosta: IBD Unit, Gastroenterology Department, University Hospital of Santiago de Compostela, 15706 Santiago de Compostela, Spain

IJERPH, 2021, vol. 18, issue 13, 1-13

Abstract: Inflammatory bowel diseases (IBDs) are chronic disabling conditions, characterized by an unpredictable course with flare-ups and periods of remission, that frequently affect young people and require lifelong medical follow-up and treatment. For years, the main endpoints of IBD treatment had been clinical remission and response, followed by biomarker normalization and mucosal healing. In the last decades, different therapies have been proved to be effective to treat IBD and the use of patient reported outcome (PRO) have become more relevant. Therefore, health-related quality of life (HRQoL) that has been defined as the value assigned to the duration of life influenced by physical and mental health, has been suggested as an important endpoint for IBD management since multiple studies have shown that IBD impairs it, both physically and psychologically. Thus, HRQoL has been included as an outcome in numerous studies evaluating different IBD therapies, both clinical trials and real-life studies. It has been assessed by using both generic and specific disease tools, and most treatments used in clinical practice have been demonstrated to improve HRQoL. The relevance of HRQoL as an endpoint for new drugs is going to increase and its management and improvement will also improve the prognosis of IBD patients.

Keywords: quality of life; Crohn’s disease; ulcerative colitis (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2021
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/18/13/7159/pdf (application/pdf)
https://www.mdpi.com/1660-4601/18/13/7159/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:18:y:2021:i:13:p:7159-:d:588296

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().